Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.
|Number of pages||3|
|Publication status||Published - 2012 Jan 1|
All Science Journal Classification (ASJC) codes